Related Experiment Video
Updated: Jan 25, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy
1University of Wisconsin, Madison Medical School, Department of Medicine, 15/220 Clinical Science Center, 600 Highland Ave, Madison, WI 53792-2454, USA. wwb@medicine.wisc.edu
Abstract:
Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.
More Related Videos
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
13:45Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
Related Concept Videos
Strategies of Self-Presentation I: Strategic Self-Presentation
Allergic Reactions
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inflammation
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Allergic Drug Reactions